Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy

Nature Medicine

Volumn 6, Issue 7, 2000, Pages 757-761

  Chun, Tae Wook ^a   Davey Jr , Richard T ^a   Ostrowski, Mario ^a   Justement, J Shawn ^a   Engel, Delphine ^a   Mullins, James I ^b   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REBOUND; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS REPLICATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; RECURRENCE; RNA, VIRAL; VIREMIA; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033914367     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/77481     Document Type: Article

References (42)

1. Gulick, R.M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy. N. Engl. J. Med. 337, 734-739 (1997).
2. Hammer, S.M. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725-733 (1997).
3. Palella, F.J. Jr. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853-860 (1998).
4. Detels, R. et al. Effectiveness of potent anti-retroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280, 1497-1503 (1998).
5. Hoyert, D.L., Kochanek, K.D. & Murphy, S.L. Deaths: final data for 1997. Natl. Vital Stat. Rep. 47, 1-104 (1999).
6. Mocroft, A. et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352, 1725-1730 (1998).
7. Dore, G.J., Brown, T., Tarantola, D. & Kaldor, J.M. HIV and AIDS in the Asia-Pacific region: an epidemiological overview. Aids 12 Suppl B, S1-10 (1998).
8. Perelson, A.S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
9. Natarajan, V. et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet 353, 119-120 (1999).
10. Furtado, M.R. et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent anti-retroviral therapy. N. Engl. J. Med. 340, 1614-1622 (1999).
11. Lewin, S.R. et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J. Virol. 73, 6099-6103 (1999).
12. Gunthard, H.F. et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J. Virol. 73, 9404-9412 (1999).
13. Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193-13197 (1997).
14. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
15. Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
16. Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512-517 (1999).
17. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
18. Chun, T.W. et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nature Med. 1, 1284-1290 (1995).
19. Chun, T.W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
20. Chun, T. W. et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95, 8869-8873 (1998).
21. Chun, T.W., Engel, D., Mizell, S.B., Ehler, L.A. & Fauci, A. S. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. 188, 83-91 (1998).
22. Ho, D.D. Toward HIV eradication or remission: the tasks ahead. Science 280, 1866-1867 (1998).
23. Schrager, L.K. & D'Souza, M.P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280, 67-71 (1998).
24. Cohen, J. Exploring how to get at - and eradicate - hidden HIV. Science 279, 1854-1855 (1998).
25. Chun, T. W. et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active antiretroviral therapy. Nature Med. 5, 651-655 (1999).
26. Chun, T.-W., Davey, R.T., Engel, D., Lane, H.C. & Fauci, A.S. Re-emergence of HIV after stopping therapy. Nature 401, 874-875 (1999).
27. Davey, R.T., Jr. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. U S A 96, 15109-15114 (1999).
28. Delwart, EL. et al. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 262, 1257-1261 (1993).
29. Delwart, E.L. & Gordon, C J. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 12, 348-354 (1997).
30. Delwart, E.C., Herring, A., Rodrigo, A.G. & Mullins, J.I. Genetic subtyping of human immunodeficiency virus using a heteroduplex mobility assay. PCR Methods and Applications. Cold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y. 4, S202-S216 (1995).
31. Wolinsky, S.M. et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255, 1134-1137 (1992).
32. Zhu, T. et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261, 1179-1181 (1993).
33. Zhang, L.Q. et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J. Virol. 67, 3345-3356 (1993).
34. Delwart, E.L., Sheppard, H.W., Walker, B.D., Goudsmit, J. & Mullins, J.I. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J. Virol.. 68, 6672-6683 (1994).
35. Wolinsky, S.M. et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272, 537-542 (1996).
36. Lukashov, V.V. & Goudsmit, J. HIV heterogeneity and disease progression in AIDS: a model of continuous virus adaptation. Aids 12 Suppl A, S43-52 (1998).
37. Cohen, O.J. & Fauci, A.S. HIV/AIDS in 1998-gaining the upper hand? JAMA 280, 87-88 (1998).
38. Chun, T.W. & Fauci, A.S. Latent reservoirs of HIV: Obstacles to the eradication of virus Proc. Natl. Acad. Sci. USA 96, 10958-10961 (1999).
39. Cavert, W. et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276, 960-964 (1997).
40. Cavert, W. & Haase, A.T. A national tissue bank to track HIV eradication and immune reconstruction. Science 280, 1865-1866 (1998).
41. Zhang, H. et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 339, 1803-1809 (1998).
42. Ostrowski, M.A. et al. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J. Virol. 72, 7772-7784 (1998).